A 28-year-old man with newly diagnosed AML-M3 (acute promyelocytic leukemia) presents with fever, petechiae, and gingival bleeding. Coagulation studies show PT 18 s, aPTT 45 s, fibrinogen 80 mg/dL, and D-dimer markedly elevated. Which investigation is most appropriate to confirm the diagnosis of AML-M3 and guide targeted therapy?

Explanation

## AML-M3 Diagnosis: Cytogenetic Confirmation Is Essential **Key Point:** Detection of t(15;17) translocation by FISH or RT-PCR is the most specific and diagnostic investigation for AML-M3 (acute promyelocytic leukemia). This translocation results in the PML-RARA fusion gene, which is: - Pathognomonic for AML-M3 - Essential for confirming the diagnosis - Mandatory for initiating all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) therapy - Used for MRD monitoring during and after treatment ## AML-M3: Diagnostic Approach ```mermaid flowchart TD A[Suspected AML-M3]:::outcome --> B[Morphology: abnormal promyelocytes]:::action B --> C{Cytogenetic confirmation}:::decision C -->|t15;17 present| D[AML-M3 confirmed]:::outcome D --> E[Initiate ATRA + ATO]:::action C -->|t15;17 absent| F[Other AML subtype]:::outcome F --> G[Standard chemotherapy]:::action B --> H[Coagulation studies]:::action H --> I[DIC assessment]:::outcome I --> J[Supportive care: FFP, platelets]:::action ``` **High-Yield:** AML-M3 is the only acute leukemia with a specific, curative targeted therapy (ATRA + ATO). Cytogenetic confirmation is mandatory before starting treatment. Without t(15;17), the diagnosis is not AML-M3, and ATRA/ATO would be inappropriate. ## Why Cytogenetics Is Diagnostic | Feature | AML-M3 | Other AML | |---|---|---| | **Morphology** | Abnormal promyelocytes with Auer rods | Variable | | **t(15;17) translocation** | **Pathognomonic (100%)** | Absent | | **PML-RARA fusion** | **Present** | Absent | | **Response to ATRA/ATO** | **Excellent (90% CR)** | Not applicable | | **Cytochemistry** | MPO+, Sudan Black+, PAS+ | Variable | **Clinical Pearl:** AML-M3 presents with severe disseminated intravascular coagulation (DIC) due to release of procoagulant substances from abnormal promyelocytes. While coagulation studies confirm DIC, they do NOT confirm the diagnosis of AML-M3. Cytogenetic testing is essential. ## Role of Each Investigation 1. **Morphology + cytochemistry:** Suggests AML-M3 (abnormal promyelocytes, MPO+) 2. **Cytogenetics (FISH/RT-PCR):** **Confirms t(15;17) — diagnostic gold standard** 3. **Coagulation studies:** Assesses DIC severity; guides supportive care (FFP, platelets, cryoprecipitate) 4. **Flow cytometry:** Confirms myeloid lineage; not specific for AML-M3